NCT07644598
MRI-based Focal Intraprostatic Simultaneous Integrated Boost (SIB) Intensification With De-escalated Adaptive-risk SBRT for Patients With Low to Intermediate Risk Prostate Cancer
Not Yet Recruiting
PHASE2Ages 18+InterventionalTreatmentGeorgetown UniversityInvestigator-initiated
~58 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Microboost SBRTWhole gland de-escalation 30 GyWhole gland de-escalation 35 Gy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of acute grade 2 or higher genitourinary toxicity
Measured over during treatment through 90 days after radiation treatment
Conditions
Where it's being run
1 sites across 1 statesDistrict of Columbia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Low risk prostate cancer:
cT1-cT2a (AJCC; 8TH edition, 2017)
Grade Group 1 (GG1)
PSA \<10 ng/mL
Intermediate risk prostate cancer:
cT2b-cT2c (AJCC; 8TH edition, 2017)
Grade Group 2 (GG2) or Grade Group 3 (GG3)
PSA 10-20 ng/mL 5. Patients with unfavorable intermediate risk prostate cancer defined by the NCCN guidelines are recommended to undergo a PSMA (Prostate-Specific Membrane Antigen) PET, then the PSMA PET must show localized disease. 6. Patients must have preferably undergone a standard of care pretreatment MRI fusion biopsy\* to identify visible intraprostatic lesions and confirm the absence of regional or distant metastatic disease, with criteria as follows:
Ability to undergo an MRI fusion biopsy;
Prostate size \<100 cc on any diagnostic MRI;
Presence of a visible prostatic lesion:
PIRADS (Prostate Imaging-Reporting and Data System) 4+ lesion, and/or
PIRADS 3 lesion with evidence of grade group 2-3
Less than or equal to 4 lesions in total allowed;
Lesion may contact the capsular edge, "possible" extracapsular extension (ECE) permitted; \*MRI fusion biopsy is preferred but if the positive core is in the same region as the target on the MRI based on a systemic biopsy, the patient can be included. 7. Genitourinary function with a baseline score ≤20 as defined by any pre-treatment IPSS questionnaire. 8. Patients are mandated to get a fiducial placement. Optional proper rectal spacer placement is recommended as determined by the treating radiation oncologist based upon whether there is overt rectal wall invasion from the hydrogel spacer or if there is minimal to no separation of the prostate-rectal interface measured at the prostate mid-gland. 9. Patients with a life expectancy of greater than 5 years as assessment by the investigator. Life expectancy can be estimated using any 1 of the following tools:
The Social Security Administration tables: https://www.ssa.gov/OACT/STATS/table4c6.html
The WHO's Life Tables by country: https://apps.who.int/gho/data/view.main.60000?lang=en
The Memorial Sloan Kettering Male Life Expectancy tool: https://www.mskcc.org/nomograms/prostate
If using a life expectancy table, life expectancy should be adjusted using the clinician's assessment of overall health as follows: best quartile of health - add 50%; worst quartile of health - subtract 50%; and middle two quartiles of health - no adjustment. See the NCCN Prostate Cancer Guidelines for more information. 10. Patients who agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agree to refrain from donating sperm, as defined below:
With a female partner of childbearing potential who is not pregnant, men who are not surgically sterile must remain abstinent or use a condom plus an additional contraceptive method, which together result in a failure rate of \< 1% per year, during the treatment period and for 1 year after treatment per local and institutional guidelines. Men must refrain from donating sperm during this same period.
With a pregnant female partner, men must remain abstinent or use a condom during the treatment period per local and institutional guidelines to avoid potential exposure to the embryo.
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not adequate methods of contraception. 11. Patients who are able to give informed consent.
Exclusion
The presence of a cardiac pacemaker, defibrillator, or other implanted metallic or electronic device which is considered MRI unsafe;
Severe claustrophobia;
Inability to lie flat for the duration of the study;
Metallic implant or device in the pelvis that might distort the local magnetic field and compromise quality of MRI;
Any other reason as determined by the investigator or treating physician. 8. Patients with an I-PSS score \>20 as defined by any pre-treatment IPSS questionnaire. 9. Patients with a prior history of transurethral resection of the prostate, TURP, Urolift, or other similar trans-urethral LUTS management procedure within the last 6 months. 10. Patients with a prior history of severe urethral stricture. 11. Patients with a prior history of pelvic irradiation. 12. Patients unable to meet dosimetric constraints 13. Patients with a prior history of non-cutaneous solid malignancy within the last 5 years. 14. Patients with a history of active and uncontrolled inflammatory bowel disease. 15. Patients who are unable to comply with follow-up visits and treatment plans.
What this trial measures
- Incidence of acute grade 2 or higher genitourinary toxicityduring treatment through 90 days after radiation treatment
Safety of the microboost technique will be determined based on the incidence of acute grade 2 or higher genitourinary adverse events (AEs). AEs will be assessed and graded according to the current version of the Common Terminology Criteria for Adverse Events (CTCAE) or severity grade when CTCAE grading does not exist. Grade 1 to 5 will be used to characterize the severity of the AE. If CTCAE grading does not exist for an AE, the severity of mild, moderate, severe, life-threatening and death due to the AE, corresponding respectively to Grades 1 - 5, will be used.